China Resources Double-Crane PharmaceuticalLtd Management
Management criteria checks 1/4
China Resources Double-Crane PharmaceuticalLtd's CEO is Wenchao Lu, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.024% of the company’s shares, worth CN¥4.73M. The average tenure of the management team and the board of directors is 1.9 years and 3 years respectively.
Key information
Wenchao Lu
Chief executive officer
CN¥2.3m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 1.9yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Is There An Opportunity With China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) 38% Undervaluation?
Jan 06
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease
Jul 16China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02CEO
Wenchao Lu (47 yo)
less than a year
Tenure
CN¥2,319,500
Compensation
Mr. Wenchao Lu is Chairman of the board of China Resources Double-Crane Pharmaceutical Co. Ltd. from September 21, 2023 and serves as its Acting President since July 2024. Mr. Lu was President of China Res...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & Acting President | less than a year | CN¥2.32m | 0.024% CN¥ 4.7m | |
| VP & Company Secretary | no data | CN¥1.11m | 0.014% CN¥ 2.7m | |
| Vice President | 3.9yrs | CN¥1.60m | 0.018% CN¥ 3.5m | |
| Vice President | 3.9yrs | CN¥1.80m | 0.025% CN¥ 4.9m | |
| Vice President | 1.9yrs | CN¥923.00k | no data | |
| Chief Financial Officer | less than a year | no data | no data |
1.9yrs
Average Tenure
49yo
Average Age
Experienced Management: 600062's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & Acting President | 2.4yrs | CN¥2.32m | 0.024% CN¥ 4.7m | |
| Director | 3.3yrs | no data | no data | |
| Independent Director | 3.5yrs | CN¥150.00k | no data | |
| Independent Director | 3.5yrs | CN¥150.00k | no data | |
| Chairman of the Supervisory Board | 3.5yrs | no data | no data | |
| Employee Supervisor | 8.3yrs | no data | no data | |
| Director | 2.8yrs | no data | no data | |
| Employee Supervisor | 3.5yrs | no data | no data | |
| Director | 2.1yrs | no data | no data | |
| Director | 1.3yrs | no data | no data | |
| Director | 1.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.0yrs
Average Tenure
55yo
Average Age
Experienced Board: 600062's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 19:12 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Resources Double-Crane Pharmaceutical Co.,Ltd. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Jessica Li | BofA Global Research |
| Helena Qiu | CCB International Securities Limited |